Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG reported an insider transaction on Form 4 for its Chief Financial Officer. The filing discloses a stock option grant covering 16,500 Common Shares at an exercise price of $67.74 on October 3, 2025. The option vests in 48 equal monthly installments beginning November 3, 2025 and carries an expiration date of October 3, 2035. The reporting person holds 16,500 derivative securities directly following the transaction.
On 09/17/2025 Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG (CRSP), reported a transaction on Form 4 showing he donated 6,000 common shares to a donor-advised fund. The Form 4 shows 201,004 shares beneficially owned directly after the transaction and 85,622 shares indirectly held through the Kulkarni 2023 GRAT. The filing is signed on 09/19/2025 and notes the donation as the reason for the disposition; the reported price is $0.00, indicating a charitable transfer rather than a sale for proceeds.
On 09/17/2025 Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG (CRSP), reported a transaction on Form 4 showing he donated 6,000 common shares to a donor-advised fund. The Form 4 shows 201,004 shares beneficially owned directly after the transaction and 85,622 shares indirectly held through the Kulkarni 2023 GRAT. The filing is signed on 09/19/2025 and notes the donation as the reason for the disposition; the reported price is $0.00, indicating a charitable transfer rather than a sale for proceeds.
Samarth Kulkarni, Chief Executive Officer and director of CRISPR Therapeutics AG (CRSP), had 25,000 restricted stock units vest on 08/16/2025, each converting to one common share. To satisfy tax withholding required by the company's RSU Settlement Policy, the reporting person sold 13,081 shares on 08/18/2025 at a price of $58.15 per share. After these transactions the reporting person directly beneficially owns 207,004 common shares and indirectly owns 85,622 common shares through the Kulkarni 2023 GRAT. The sale was described as mandated to cover tax withholding and not a discretionary trade.
CRISPR Therapeutics director Douglas A. Treco reported buying common shares of the company. On August 6, 2025, he made an open-market purchase of 20,000 common shares at a weighted average price of $57.03 per share. Following this transaction, he directly owns 22,000 common shares of CRISPR Therapeutics.
CRISPR Therapeutics (Nasdaq: CRSP) filed an 8-K reporting new in-vivo cardiovascular data.
CTX310: Phase 1 trial shows up to 82% triglyceride and 86% LDL-C reductions at 0.8 mg/kg, with no clinically significant liver-enzyme changes.
CTX320: Phase 1 enrollment ongoing; next clinical update shifted to H1 2026 to incorporate emerging Lp(a) insights.
CTX340: IND/CTA-enabling studies progressing for refractory hypertension.
The company highlights validated surrogate endpoints, a favorable safety profile, and includes customary forward-looking statement disclaimers.